A comprehensive resource for heart and vascular services.

  • Increase/Decrease Text Size
  • Print This Page
Back to Results Back to Search

Charles A. Leath III, M.D.

Associate Professor

Associate Professor, Division of Gynecologic Oncology

  • Primary Clinic Location
  • Hospital Affiliation

    Women & Infants Center

  • Print this profile

Credentials

Education and Training
  • Medical School
    • Medical University of South Carolina
    • 1998
  • Residency
    • UAB Hospital
    • 2002
  • Fellowship
    • UAB Hospital
    • 2005
Certifications
  • American Board of Obstetrics & Gynecology 2005
  • American Board of Obstetrics & Gynecology-Gynecologic Oncology 2008
  • DaVinci Robotic Surgical System Trained Surgeon 2008

Clinic Information

Locations and Directions
Women & Infants Center
1700 6th Ave South
Birmingham, AL 35233

Clinical Interests

Clinical Interests
  • Uterine (endometrial cancer)
  • Ovarian cancer
  • Cervical Cancer
  • Vulvar Cancer
  • Vaginal Cancer
  • Gestational Trophoblastic Disease Complex Benign Gynecologic Surgical Conditions
  • Cervical cancer therapeutics
  • Novel therapeutics for ovarian
  • Cervical cancer screening
  • Genetics of gynecologic cancers
  • Gynecology oncology
  • Chemotherapeutic trials
  • Clinical Trials
  • Supportive Care
  • Minimally invasive and robotic surgery Clinical trials.
     

Publications

Publications

1. Straughn JM Jr., Huh WK, Kelly FJ, Leath CA III, Kleinberg MJ, Hyde J Jr., Numnum TM, Zhang Y, Soong S, Austin Jr. JM, Partridge EE, Kilgore LC, Alvarez RD. Conservative management of Stage I Endometrial Carcinoma after Surgical Staging. Gynecol Oncol 84(2): 194-200, 2002

2. Barnes MN, Berry WD, Straughn JM Jr., Kirby TO, Leath CA, Huh WK, Grizzle WE, Partridge EE. A Pilot Study of Ovarian Cancer Chemoprevention Using Medroxyprogesterone Acetate in an Avian Model of Spontaneous Ovarian Carcinogenesis. Gynecol Oncol 87(1): 57-63, 2002

3. Leath CA III, Straughn JM Jr., Huh WK, Conner MG. Uterine leiomyosarcoma metastatic to the thyroid. Obstet Gynecol 100(5 Pt 2): 1122-4, 2002

4. Leath CA III, Ramsey PS.  guest editorial: Stump the professor. Obstet Gynecol Surv 57(12): 785-7, 2002

5. Leath CA III, Huh WK, Conner MG, Barnes MN III. Primary extrarenal rhabdoid tumor of the ovary: A case report. J Reprod Med 48(4): 283-6, 2003

6. Huh WK, Powell MA, Leath CA III, Straughn JM Jr., Herzog TJ, Cohn DE, Fowler JM, Gold MA, Falkner CA, Carey DE, Partridge EE, Kilgore LC. Uterine papillary serous carcinoma: Comparisons of outcomes of surgical stage I patients with and without adjuvant therapy. Gynecol Oncol 91(3): 470-5, 2003

7. Estes JM, Rocconi R, Straughn JM Jr., Bhoola S, Leath CA III, Alvarez RD, Kilgore LC, Huh WK. Complications of indwelling venous access devices in patients with gynecologic malignancies. Gynecol Oncol 91(3): 591-5, 2003

8. Leath CA III, Straughn JM Jr., Bhoola SM, Partridge EE, Kilgore LC, Alvarez RD. The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy. Gynecol Oncol 92(1): 215-219, 2004

9. Leath CA III, Straughn JM Jr., Conner MG, Barnes MN III, Alvarez RD, Partridge EE, Huh WK. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: A pilot study. J Reprod Med 49(2): 71-8, 2004

10. McGwin Jr. G, Russell SR, Rux RL, Leath CA III, Valent F, Rue LW III. Knowledge, beliefs, and practices concerning seat belt use during pregnancy. J Trauma 56(3): 670-5, 2004

11. Leath CA III, Douglas JT, Curiel DT, Alvarez RD. Single-chain antibodies: A therapeutic modality for cancer gene therapy (Review). Int J Oncol 24(4): 765-771, 2004

12. Zhu ZB, Makhija SM, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Yamamoto M, Alvarez RD, Curiel DT. Transcriptional targeting of adenoviral vector through the CXCR4 tumor specific promoter. Gene Ther 11(7): 645-8, 2004

13. Zhu ZB, Makhija SM, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, Barker S, Yamamoto M, Li F, Alvarez RD, Curiel DT. Transcriptional targeting of tumors with a novel tumor survivin promoter. Cancer Gene Ther 11(4): 256-62, 2004

14. Havrilesky LJ, Leath CA, Huh WK, Calingaert B, Bentley R, Soper JT, Secord AA. Radical Hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. Gynecol Oncol 93(2): 429-34, 2004

15. Wu H, Han T, Lam JT, Leath CA, Dmitriev I, Kashentseva E, Barnes MN, Alvarez RD, Curiel DT. Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy. Gene Ther 11(10): 874-8, 2004

16. Preuss MA, Lam JT, Wang M, Leath CA III, Kataram M, Mahareshti PJ, Alvarez RD, Curiel DT. Transcriptional Blocks Limit Adenoviral Replication in Primary Ovarian Tumor. Clin Cancer Res 10: 3189-3194, 2004

17. Leath CA, Kataram M, Bhagavatula P, Gopalkrishnan RV, Dent P, Fisher PB, Pereboev A, Carey D, Lebedeva IV, Haisma HJ, Alvarez RD, Curiel DT, Mahareshti PJ. Infectivity enhanced adenoviral mediated mda-7/IL-24 gene therapy for ovarian carcinoma. Gynecol Oncol 94(2): 352-62, 2004

18. Rocconi R, Leath CA III, Johnson WM III, Barnes MN III, Conner MG. Primary Lung Large Cell Carcinoma Metastatic to the Vulva: A Case Report and Review of the Literature. Gynecol Oncol 94(3): 829-31, 2004

19. Leath CA III, Straughn JM Jr., Estes JM, Kirby TO, Bhoola SB, Barnes MN III, Kilgore LC, Alvarez RD. The impact of aborted radical hysterectomy in patients with cervical carcinoma. Gynecol Oncol 95(1): 204-7, 2004

20. Straughn JM Jr., Numnum TM, Rocconi RP, Leath CA III, Partridge EE. A Cost-Effectiveness Analysis of Screening Strategies for Cervical Intraepithelial Neoplasia. J Low Genital Tract Dis 8(4): 280-4, 2004

21. Leath CA III, Barnes MN III, Huh WK. Protrusio acetabuli presenting as a complex pelvic mass following total hip arthroplasty. Obstet Gynecol 104(5 Pt 2): 1187-9, 2004

22. Im SS, Gordon AN, Buttin BM, Leath CA III, Gostout BS, Shah C, Hatch KD, Wang J, Berman ML. Validation of SGO/ACOG referral guidelines for women with pelvic masses. Obstet Gynecol 105(1): 35-41, 2005

23. Numnum TM, Kirby TO, Leath CA III, Huh WK, Alvarez RD, Straughn JM Jr. A prospective evaluation of “see and treat” in women with HSIL pap smear results: Is this an appropriate strategy? J Low Genital Tract Dis 9(1): 2-6, 2005

24. Rocconi RP, Estes JM, Leath CA III, Kilgore LC, Huh WK, Straughn JM Jr. Management strategies for Stage IB2 Cervical Cancer: A cost-effectiveness analysis. Gynecol Oncol 97(2): 387-94, 2005

25. Numnum TM, Leath CA III, Straughn JM Jr., Conner MG, Barnes MN III. Occult choriocarcinoma discovered by positron emission tomography/computed tomography following a successful pregnancy. Gynecol Oncol 97(2): 713-5, 2005

26. Leath CA III, Straughn JM Jr., Kirby TO, Huggins A, Partridge EE, Parham GP. Predictors of outcomes for women with cervical carcinoma. Gynecol Oncol 99(2): 433-7, 2005

27. Kendrick JE IV, Leath CA III, Melton SM, Straughn JM Jr. Use of a Fascial Prosthesis for management of abdominal compartment syndrome secondary to obstetrical hemorrhage. Obstet Gynecol 107(2 Pt 2): 493-6, 2006

28. Kirby TO, Leath CA III, Kilgore LC. Surgical Staging in Endometrial Cancer (Review). Oncology 70(1): 45-63, 2006

29. Rocconi RP, Straughn JM Jr., Leath CA III, Kilgore LC, Huh WK, Barnes MN III, Partridge EE, Alvarez RD. Pegylated liposomal doxorubicin (Doxil®) consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally-debulked advanced stage ovarian cancer patients. Oncologist 11(4): 336-41, 2006

30. Estes JM, Leath CA, Williams S, Modiano MR, Sawyer M, Cohn D, Straughn JM, Barnes MN, Alvarez RD. Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent ovarian cancer. Gynecol Oncol 102(2): 338-42, 2006

31. Numnum TM, Leath CA III, Straughn JM Jr. A case of synchronous primary endometrial and ovarian carcinoma in a patient diagnosed with marantic endocarditis. Obstet Gynecol 108(3 Pt 2): 758-50, 2006

32. Spannuth W, Leath CA III, Conner MG, Alvarez RD. Inflammatory pseudotumor of pelvic lymph nodes: A case report. Obstet Gynecol 108(3 Pt 2): 779-82, 2006

33. Estes JM, Leath CA III, Straughn JM Jr., Rocconi RP, Kirby TO, Huh WK, Barnes MN III. Bowel resection at the time of primary Debulking for epithelial ovarian carcinoma: Outcomes in patients treated with platinum/taxane based chemotherapy. J Am Coll Surg 203(4): 527-32, 2006

34. Leath CA III, Kendrick JE IV, Numnum TM, Straughn JM Jr., Rocconi RP, Sfakianos GP, Lang JD Jr. Outcomes of gynecologic oncology patients admitted to the intensive care unit following surgery: A university teaching hospital experience. Int J Gynecol Cancer 16(5):1766-9, 2006

35. Spannuth WA, Leath CA III, Huh WK, Barnes MN III, Davidson SA, Kilgore LC, Partridge EE, Austin JM Jr., Alvarez RD. A prospective phase II trial of weekly topotecan for patients with platinum-sensitive recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol 104 (3): 591-5, 2007

36. Parini CL, Mathis D, Leath CA III. Occult metastatic lung carcinoma presenting as locally advanced uterine carcinosarcoma on positron emission tomography/computed tomography imaging. Int J Gynecol Cancer 17(3):731-4, 2007

37. Leath CA III, Huh WK, Hyde J Jr., Cohn DE, Resnick KE, Taylor NP, Powell MA, Mutch DG, Bradley WH, Geller MA, Argenta PA, Gold MA. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 105(3): 630-4, 2007

38. Leath CA III, Numnum TM, Strauhn JM Jr., Rocconi RP, Huh Wk, Kilgore LC, Partridge EE. Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: a retrospective university experience. Int J Gynecol Cancer 17(5):998-1002, 2007

39. Moore KN, Moxley KM, Fader AN, Axtell AE, Rocconi RP, Abaid LN, Cass IA, Rose PG, Leath CA III, Rutledge T, Blankenship D, Gold MA. Serous fallopian tube carcinoma: A retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol 107(3):398-403, 2007

40. Leath CA III, Decherd ME, Wilder JL. Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. Gynecol Oncol 110(2):268-9, 2008

41. Kendrick JE, Numnum TM, Estes JM, Kimball KJ, Leath CA, Straughn JM Jr. Conservative management of postoperative fever in gynecologic patients undergoing major abdominal or vaginal operations. J Am Coll Surg 207(3):393-7, 2008

42. Lowery WJ, Difurio MJ, Sundborg MJ, Leath CA III. Cervical signet-ring cell carcinoma presenting as a synchronous primary carcinoma with uterine adenocarcinoma. Mil Med 174(2):212-3, 2009

43. Leath CA III, Numnum TM, Kendrick JE IV, Fredrick PJ, Rocconi RP, Conner MG, Straughn JM Jr. Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: Implications for adjuvant therapy. Int J Gynecol Cancer 19(5):888-91, 2009

44. Lowery WJ, Song WS, Leath CA III. Hot and blue: Lymphoscintigraphy might be useful in cervical cancer surgery. Am J Obstet Gynecol 201(2):223.e1-2, 2009

45. Phippen NT, Leath CA III. Weekly topotecan and daily thalidomide in patients with recurrent epithelial ovarian cancer: A report of 2 cases. J Reprod Med 54(9):583-6, 2009

46. Phippen NT, Lowery WJ, Leath CA III, Kost ER. Epithelioid trophoblastic tumor masquerading as invasive squamous cell carcinoma of the cervix after an ectopic pregnancy. Gynecol Oncol 117(2):387-8, 2010

47. Keyser EA, Reed BG, Lowery WJ, Sundborg MJ, Winter WE III, Ward JA, Leath CA III. Hospice enrollment for terminally ill patients with gynecologic malignancies: Impact on outcomes and interventions. Gynecol Oncol 118(3):274-7, 2010

48. Gonzalez MN, DiFurio MJ, Sundborg MJ, Leath CA III. Undifferentiated uterine sarcoma presenting as a pathologic humerus fracture. Mil Med 175(9):691-2, 2010

49. Shaltz AT, Leath CA III, Wiedenhoefer JF, Sundborg MJ. Reaction to a surgical implant foreign body masquerading as recurrent uterine sarcoma. Obstet Gynecol 117(2 Pt 2): 450-2, 2011

50. Phippen NT, Lowery WJ, Banks NB, Leath CA III. Multiple synchronous primary ovarian malignancies in a patient with a MLH-1 mutation: Impact on potential fertility preservation. Gynecol Oncol 121(3): 637-8, 2011

51. Orr JM, Barnett JC, Leath CA III. Incidence of subsequent abnormal cytology in cervical cancer patients completing five-years of post treatment surveillance without evidence of recurrence. Gynecol Oncol 122(3):501-4, 2011

52. Reed BG, Lowery WJ, Keyser EA, Kost ER, Sundborg MJ, Winter WE III, Landt C, Leath CA III. Surgically managed stage I endometrial cancer in a low-volume center: Outcomes and complications in a military residency program. Am J Obstet Gynecol 205(4):356.e1-5, 2011

53. Phippen NT, Lowery WJ, Barnett JC, Hall LA, Landt C, Leath CA III. Evaluation of the patient-generated subjective global assessment (PG-SGA) as a predictor of febrile neutropenia in gynecologic cancer patients receiving combination chemotherapy: A pilot study. Gynecol Oncol 123(2): 360-4, 2011

54. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt CH, Brown JV, Covens A, Nagarkar RV, Davy M, Leath CA III, Nguyen H, Stepan DE, Weinreich DM, Tassoudji M, Sun Y-N, Vergote IB. A randomized, double-blind, placebo-controlled phase 2 study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30(4):362-71, 2012

55. Lowery WJ, Leath CA, Robinson RD. Robotic surgery applications in the management of gynecologic malignancies. J Surg Oncol 105(5): 481-7, 2012

56. Zierbarth A, Smith HJ, Killian ME, Nguyen NA, Durst JK, Subramaniam A, Kim KH, Leath CA III, Straughn JM, Alvarez RD. Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the era of modern chemoradiation therapy. Gynecol Oncol 126(1): 69-72, 2012

57. Keyser EA, Reed BG, Gonzalez-Brown V, Fausett B, Staat BC, Leath CA. Peripartum cardiomyopathy and acute fatty liver of pregnancy: one patient with two zebras. Mil Med 177(4):470-3, 2012

58. Phippen NT, Leath CA III, Chino JP, Jewell EL, Havrilesky LJ, Barnett JC. Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with Stage IIB to IVA carcinoma of the cervix. Gynecol Oncol 127 (2): 267-72, 2012

59. Barnett JC, Leath CA III. Re: The utilization of palliative care in gynecologic oncology patients near the end of life. Gynecol Oncol 127(3): 678-9, 2012
 

Research

Research Interests
  • Primarily cervical and ovarian cancer clinical trials
  • Immunologic Responses to primary chemoradiation therapy in locally advanced cervical cancer (Forthcoming)
  • Predictors of chemotherapy resistance in patients undergoing Neoadjuvant chemotherapy for advanced stage ovarian cancer (Forthcoming)

Attention UAB Physicians

If you are a physician on the UAB medical staff and would like to modify your profile, please e-mail your changes to the program administrator

Update Profile
top